•
Sep 30, 2022

Bausch Health Q3 2022 Earnings Report

Bausch Health's third-quarter performance reflected resilience with revenue of $2.046 billion, a decrease of 3% but an organic increase of 2%, driven by growth in key segments and strategic debt reduction.

Key Takeaways

Bausch Health reported a revenue of $2.046 billion for Q3 2022, a 3% decrease compared to Q3 2021, but showed a 2% increase on an organic basis. The company highlighted top-line improvements in several segments and a successful debt exchange offer that reduced debt by $2.5 billion. They have updated full year guidance.

Revenues of $2.046 billion, down 3% reported, up 2% organic basis

Third quarter sales improved sequentially, notably Salix, International, and Solta

Successful debt exchange offer reduces debt by $2.5 billion

Company updates full year guidance

Total Revenue
$2.05B
Previous year: $2.11B
-3.1%
EPS
$0.76
Previous year: $1.15
-33.9%
Adjusted EBITDA
$766M
Previous year: $885M
-13.4%
Cash from Operations
-$1.26B
Gross Profit
$1.46B
Previous year: $1.53B
-4.4%
Cash and Equivalents
$486M
Previous year: $690M
-29.6%
Free Cash Flow
-$1.32B
Previous year: $501M
-362.9%
Total Assets
$26.3B
Previous year: $29.3B
-10.1%

Bausch Health

Bausch Health

Bausch Health Revenue by Segment

Forward Guidance

Bausch Health updated its consolidated guidance for the full year 2022 as follows: •Full year revenue range of $8.0 - $8.17 billion compared with prior guidance of $8.05 - $8.22 billion •Full year revenues flat to up 2% on an organic basis (unchanged) •Full year Adjusted EBITDA (non-GAAP)1 range of $2.99 - $3.09 billion compared with prior guidance of $3.02 - $3.12 billion

Revenue & Expenses

Visualization of income flow from segment revenue to net income